3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Phase 2
1
Status
Recruiting
3
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Other hematologic neoplasm
3
Lymphoid
2
Genitourinary
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
27
Neoplasms
8
Lung Neoplasms
6
Neoplasms by Site
3
Neoplasm Metastasis
3
Lymphoma, Large-Cell, Anaplastic
3
Hematologic Neoplasms
3
Breast Neoplasms
3
Brain Neoplasms
3
Thyroid Neoplasms
2
Sarcoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Gastrointestinal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Urinary Bladder Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Solid Tumors
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Rare Tumour
1
Rare Tumor
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Interventions
Cyclophosphamide
87
fludarabine
74
Tacrolimus
45
fludarabine phosphate
44
Mycophenolic Acid
42
Whole-Body Irradiation
41
Busulfan
35
Melphalan
31
Antilymphocyte Serum
24
thymoglobulin
22
Methotrexate
22
Rituximab
21
Standard of Care
20
Sirolimus
20
Azacitidine
20
venetoclax
19
Thiotepa
19
Stem Cell Transplantation
18
Granulocyte Colony-Stimulating Factor
18
Practice Guidelines as Topic
16
Cytarabine
16
Nivolumab
15
Filgrastim
15
Dexamethasone
14
Cyclosporine
13
Bortezomib
13
Mesna
12
Peripheral Blood Stem Cell Transplantation
11
trametinib
10
Specimen Handling
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Interventional
×
Hematologic Neoplasms
×
alectinib
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770037
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled
NCT05159245
2024-07-15
FINPROVE
Helsinki University Central Hospital
Phase 2
Recruiting
250 enrolled